\(
\def\WIPO{World Intellectual Property Organisation}
\)
Lucence: Lighting up the Future of Cancer Care
2023
Formats
| Format | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DataCite | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS |
Citer
Détails
Titre
Lucence: Lighting up the Future of Cancer Care
Type d’élément
Journal article
Description
1 article.
Résumé
One in three people will get cancer in their lifetime. This stark statistic makes early detection of cancer - when the disease is more treatable and curable - a “must.” A hyper-sensitive blood test developed by Lucence, a precision oncology company based in Singapore and the USA, promises to make early detection a reality. Through its ground-breaking technology, Lucence is working to improve cancer care and cure rates through a simple blood test. Its ultra-sensitive liquid biopsy tests make it possible to profile cancer accurately, rapidly and affordably with a single blood draw, allowing physicians to make better treatment decisions and improve health outcomes. Dr. Min-Han Tan, Founder and CEO of Lucence, talks to WIPO Magazine about his company’s commitment to saving the lives of cancer patients around the world through earlier detection of the disease.
Série
Ressources liées
Traductions
Publié
Geneva, Switzerland : World Intellectual Property Organization, 2023.
Langue
Anglais
Le document apparaît dans